Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)-Reference-Cited by-同舟云学术

Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)

Published:2023-02-04 Issue:1 Volume:6 Page:17-22
ISSN:2582-0370
Container-title:Asploro Journal of Biomedical and Clinical Case Reports
language:en
Short-container-title:Asp Biomed Clin Case Rep

Author:

OKADA Masaki¹,BANDO Hiroshi²^ORCID,IWATSUKI Noboru¹,SAKAMOTO Kazuki¹,OGAWA Tomoya¹

Affiliation:

1. Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan

2. Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan; Tokushima University/Medical research, Tokushima, Japan

Abstract

Background: Recent diabetic focus includes imeglimin (Twymeeg). Case Presentation: The case was an 83-year-old female with 19 years of type 2 diabetes (T2D) associated with recent treatment for dementia. Result: HbA1c decreased from 10.0% to 6.6% for 4 months by Twymeeg 2000 mg/day. For neuropsychiatric symptoms in dementia, memantine and tiapride were provided and controlled. Furthermore, zinc acetate hydrate (Novelzin) was continued for T2D and dementia. Discussion and Conclusion: Twymeeg administration was effective as the results of Trials of IMeglimin for Efficacy and Safety (TIMES) 2 and 3. Perspectives on the efficacy of zinc were discussed including Alzheimer’s-Plus with low zinc (APLZ).

Publisher

Asploro Open Access Publications

Subject

General Medicine

Reference24 articles.

1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supple 1):S10-S18. [PMID: 36507639]

2. Saleem SM, Bhattacharya S, Deshpande N. Non-communicable diseases, type 2 diabetes, and influence of front of package nutrition labels on consumer’s behaviour: Reformulations and future scope. Diabetes Metab Syndr. 2022 Feb;16(2):102422. [PMID: 35150963]

3. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Jeffrie Seley J, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 13. Older Adults: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S216-29. [PMID: 36507638]

4. Bando H, Hayashi K, Sumitomo K, Miki K, Kamoto A. Rapid Reduction of HbA1c and Weight in Elderly Patient with Type 2 Diabetes (T2D) And Depression by Oral Semaglutide (Rybelsus). Asp Biomed Clin Case Rep. 2022 Jul 23;5(2):73-78.

5. Okada M, Bando H, Iwatsuki N, Ogawa T, Sakamoto K. Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM). Asp Biomed Clin Case Rep. 2022 Feb 21;5(1):33-37.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg);Asploro Journal of Biomedical and Clinical Case Reports;2023-06-12

2. Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy;Asploro Journal of Biomedical and Clinical Case Reports;2023-04-14

3. Detail Measurement of Pre-Prandial and Post-Prandial Blood Glucose during Imeglimin (Twymeeg) Treatment;Asploro Journal of Biomedical and Clinical Case Reports;2023-03-02